EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical and Experimental Immune Tolerance in Pediatric Liver Transplantation

Ahmed M Elsabbagh iD, Yannis Hadjiyannis iD, Julien Vionnet iD, Angus W Thomson iD

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70260 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von Ahmed M Elsabbagh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Immune Tolerance, Transplantation Tolerance. Die Arbeit nennt 190 Literaturangaben. Gefördert von: NIAID NIH HHS, University of Pittsburgh Medical Center (UPMC), Burroughs Welcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric liver transplantation (LT) is a life‐saving therapy, uniquely characterized by a favorable immunologic profile and a higher incidence of immune tolerance among long‐term survivors. The liver's inherent tolerogenic environment, combined with the immunologic immaturity and thymic activity of children, may promote this phenomenon. Achieving operational tolerance (OT) minimizes lifelong immunosuppression (IS) toxicity, improving allograft longevity and quality of life. This review synthesizes current clinical and mechanistic evidence on immune tolerance in pediatric LT, evaluating the prevalence and outcomes of IS‐withdrawal trials (e.g., WISP‐R, iWITH, LIFT, OPTIMAL, SPLIT, ALLTOL). It also examines histopathologic correlations, clinical and immunologic predictors, and underlying molecular mechanisms and cell types such as regulatory T‐cells, IL‐10, TGF‐β, CTLA‐4 pathways, and so forth. It addresses the challenges and limitations in translating these advances into widespread clinical practice. OT is achievable in 15%–60% of carefully selected pediatric LT recipients in structured IS withdrawal protocols. Tolerant children maintain normal graft function, excellent survival, and preserved immunity without increased infection risk or the cumulative toxicities of chronic IS. Predictors of OT include younger age at transplant or withdrawal, non‐immune disease etiology, longer post‐transplant duration, and absence of donor‐specific antibodies. Mechanistically, the liver's unique microenvironment, characterized by specific molecular pathways and cellular interactions, fosters immune regulation. Immune tolerance in pediatric LT is clinically attainable and significantly reduces the burden of lifelong IS. Progress in biomarker‐guided and protocolized withdrawal has improved safety, yet standardization and broader implementation remain challenges. Continued mechanistic and translational research is essential to optimize patient selection, refine monitoring strategies, and safely extend IS minimization to all pediatric LT recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationImmune ToleranceTransplantation ToleranceHumansChildImmunosuppressive AgentsAnimalsGraft SurvivalImmunosuppression TherapyGraft RejectionT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

allotransplantationcell therapyimmunologyliver transplantationpediatricregulatory therapiestolerance

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Hillman Center for Pediatric Transplantation, Liver and Intestinal Transplant Surgery, UPMC Children's Hospital, Pittsburgh, Pennsylvania, USA.
  • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Transplantation Center, Service of Immunology and Allergy, and Service of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland.
  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Ahmed M Elsabbagh, Yannis Hadjiyannis, Julien Vionnet, Angus W Thomson

Förderung

  • NIAID NIH HHS
  • University of Pittsburgh Medical Center (UPMC)
  • Burroughs Welcome Fund
  • Starzl Transplantation Institute Research Development Funds

Zitieren

APA

Elsabbagh, A. M., Hadjiyannis, Y., Vionnet, J., & Thomson, A. W. (2026). Clinical and Experimental Immune Tolerance in Pediatric Liver Transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.70260

Vancouver

Elsabbagh AM, Hadjiyannis Y, Vionnet J, Thomson AW. Clinical and Experimental Immune Tolerance in Pediatric Liver Transplantation. Pediatric Transplantation. 2026. doi:10.1111/petr.70260

BibTeX
@article{Elsabbagh2026,
  author = {Elsabbagh, Ahmed M and Hadjiyannis, Yannis and Vionnet, Julien and Thomson, Angus W},
  title = {Clinical and Experimental Immune Tolerance in Pediatric Liver Transplantation},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70260}
}
Kostenlos starten →